Salarius Pharmaceuticals (SLRX) Short Interest Ratio & Short Volume → Biden replacement revealed? (From Paradigm Press) (Ad) Free SLRX Stock Alerts $0.47 +0.01 (+2.17%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Salarius Pharmaceuticals Short Interest DataCurrent Short Volume73,600 sharesPrevious Short Volume115,600 sharesChange Vs. Previous Month-36.33%Dollar Volume Sold Short$36,726.40Short Interest Ratio / Days to Cover0.6Last Record DateApril 30, 2024Outstanding Shares4,780,000 sharesFloat Size4,450,000 sharesShort Percent of Float1.65%Today's Trading Volume31,849 sharesAverage Trading Volume86,571 sharesToday's Volume Vs. Average37% Short Selling Salarius Pharmaceuticals ? Sign up to receive the latest short interest report for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatSLRX Short Interest Over TimeSLRX Days to Cover Over TimeSLRX Percentage of Float Shorted Over Time Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. Salarius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202473,600 shares $36,726.40 -36.3%1.7%0.6 $0.50 4/15/2024115,600 shares $57,800.00 -57.0%2.6%1 $0.50 3/31/2024268,900 shares $142,140.54 +1,767.4%6.7%2.4 $0.53 3/15/202414,400 shares $9,360.00 -20.0%0.4%0.1 $0.65 2/29/202418,000 shares $12,060.00 +227.3%0.5%0.6 $0.67 2/15/20245,500 shares $3,245.00 -33.7%0.2%0.2 $0.59 Get the Latest News and Ratings for SLRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/20248,300 shares $4,556.70 +36.1%0.2%0.2 $0.55 1/15/20246,100 shares $3,721.00 -37.1%0.2%0.2 $0.61 12/31/20239,700 shares $6,305.00 +38.6%0.3%0.3 $0.65 12/15/20237,000 shares $4,515.00 -71.9%0.2%0.1 $0.65 11/30/202324,900 shares $17,679.00 -56.0%0.7%0.4 $0.71 11/15/202356,600 shares $40,752.00 -22.7%1.6%1.1 $0.72 10/31/202373,200 shares $61,334.28 +136.9%2.3%1.2 $0.84 10/15/202330,900 shares $21,321.00 +62.6%0.9%0.5 $0.69 9/30/202319,000 shares $12,500.08 -6.4%0.6%0.3 $0.66 9/15/202320,300 shares $17,395.07 -26.5%0.6%0.4 $0.86 8/31/202327,600 shares $24,285.24 +162.9%0.8%0.5 $0.88 8/15/202310,500 shares $7,490.70 +54.4%0.3%0.2 $0.71 7/31/20236,800 shares $6,249.20 -60.9%0.2%0.1 $0.92 7/15/202317,400 shares $19,314.00 -44.8%0.6%0.2 $1.11 6/30/202331,500 shares $46,935.00 -41.2%1.0%0.3 $1.49 6/15/202353,600 shares $85,224.00 +9.6%1.7%0.5 $1.59 5/31/202348,900 shares $68,949.00 -48.4%2.1%0.5 $1.41 5/15/202394,700 shares $136,368.00 -16.1%4.2%1 $1.44 4/30/2023112,800 shares $200,784.00 -11.9%5.4%1.3 $1.78 4/15/2023128,000 shares $220,160.00 +6.1%6.1%2.5 $1.72 3/31/2023120,700 shares $230,537.00 -4.2%5.8%0.8 $1.91 3/15/2023126,000 shares $255,780.00 -4.0%6.6%0.7 $2.03 2/28/2023131,300 shares $279,669.00 +16.7%6.8%0.7 $2.13 2/15/2023112,500 shares $252,000.00 +11.3%5.9%0.6 $2.24 1/31/2023101,100 shares $260,838.00 +37.7%5.2%0.6 $2.58 1/15/202373,400 shares $194,510.00 +272.6%3.8%0.4 $2.65 12/30/202219,700 shares $30,141.00 -46.6%1.0%0.3 $1.53 12/15/202236,900 shares $55,719.00 +93.2%1.9%0.8 $1.51 11/30/202219,100 shares $36,863.00 -12.0%1.0%0.4 $1.93 11/15/202221,700 shares $46,655.00 +100.9%1.1%0.5 $2.15 10/31/202210,800 shares $21,924.00 -31.2%0.5%0.3 $2.03 10/15/202215,700 shares $71,042.50 -95.8%0.8%0.4 $4.53 9/30/2022371,000 shares $72,345.00 -8.4%N/A0.9 $0.20 9/15/2022405,000 shares $95,904.00 +9.6%N/A0.8 $0.24“Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. SLRX Short Interest - Frequently Asked Questions What is Salarius Pharmaceuticals' current short interest? Short interest is the volume of Salarius Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 73,600 shares of SLRX short. 1.65% of Salarius Pharmaceuticals' shares are currently sold short. Learn More on Salarius Pharmaceuticals' current short interest. What is a good short interest ratio for Salarius Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SLRX shares currently have a short interest ratio of 1.0. Learn More on Salarius Pharmaceuticals's short interest ratio. What is a good short interest percentage for Salarius Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.65% of Salarius Pharmaceuticals' floating shares are currently sold short. Is Salarius Pharmaceuticals' short interest increasing or decreasing? Salarius Pharmaceuticals saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 73,600 shares, a decrease of 36.3% from the previous total of 115,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Salarius Pharmaceuticals' float size? Salarius Pharmaceuticals currently has issued a total of 4,780,000 shares. Some of Salarius Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Salarius Pharmaceuticals currently has a public float of 4,450,000 shares. How does Salarius Pharmaceuticals' short interest compare to its competitors? 1.65% of Salarius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Salarius Pharmaceuticals: Sonoma Pharmaceuticals, Inc. (0.30%), Altamira Therapeutics Ltd. (6.57%), Avenue Therapeutics, Inc. (3.26%), Notable Labs, Ltd. (0.08%), Dermata Therapeutics, Inc. (1.28%), Onconetix, Inc. (0.31%), Clearmind Medicine Inc. (5.51%), CNS Pharmaceuticals, Inc. (0.31%), 60 Degrees Pharmaceuticals, Inc. (1.31%), Agile Therapeutics, Inc. (12.68%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Salarius Pharmaceuticals stock? Short selling SLRX is an investing strategy that aims to generate trading profit from Salarius Pharmaceuticals as its price is falling. SLRX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Salarius Pharmaceuticals? A short squeeze for Salarius Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SLRX, which in turn drives the price of the stock up even further. How often is Salarius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SLRX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: SNOA Short Interest CYTO Short Interest ATXI Short Interest NTBL Short Interest DRMA Short Interest ONCO Short Interest CMND Short Interest CNSP Short Interest SXTP Short Interest AGRX Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SLRX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersCharles Payne Demystifies OptionsUnstoppable ProsperityGold Set to EXPLODE!Gold Safe ExchangeBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyWhy Is Gold On a MASSIVE rally? Huge AlertsProtect Your Bank Account Before It’s Too LateWeiss Ratings